Literature DB >> 17713545

FOXP3+ regulatory T cells in cutaneous T-cell lymphomas: association with disease stage and survival.

L M Gjerdrum1, A Woetmann, N Odum, C M Burton, K Rossen, G L Skovgaard, L P Ryder, E Ralfkiaer.   

Abstract

FOXP3 is a unique marker for CD4+CD25+ regulatory T cells (Tregs). In solid tumours, high numbers of Tregs are associated with a poor prognosis. Knowledge about the implications of Tregs for the behaviour of haematological malignancies is limited. In this study, skin biopsies from 86 patients with mycosis fungoides (MF) and cutaneous T-cell lymphoma (CTCL) unspecified were analysed for the expression of FOXP3 on tumour cells and tumour-infiltrating Tregs. Labelling of above 10% of the neoplastic cells was seen in one case classified as an aggressive epidermotropic CD8+ cytotoxic CTCL. In the remaining 85 cases, the atypical neoplastic infiltrate was either FOXP3 negative (n=80) or contained only very occasional weakly positive cells (n=5). By contrast, all biopsies showed varying numbers of strongly FOXP3+ tumour-infiltrating Tregs. MF with early or infiltrated plaques had significantly higher numbers of FOXP3+ Tregs than CTCL unspecified or advanced MF with tumours or transformation to large cell lymphoma. An analysis of all patients demonstrated that increasing numbers of FOXP3+ Tregs were associated with improved survival in both MF and CTCL unspecified. In conclusion, our data indicate that the presence of FOXP3+ Tregs in CTCL is associated with disease stage and patient survival.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17713545     DOI: 10.1038/sj.leu.2404913

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  37 in total

1.  Targeted therapies: Denileukin diftitox--a step towards a 'magic bullet' for CTCL.

Authors:  Marshall E Kadin; Eric C Vonderheid
Journal:  Nat Rev Clin Oncol       Date:  2010-08       Impact factor: 66.675

Review 2.  Targeting cyclooxygenase-2 in hematological malignancies: rationale and promise.

Authors:  M P Bernard; S Bancos; P J Sime; R P Phipps
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

3.  Mogamulizumab Forecast: Clearer Patients, with a Slight Chance of Immune Mayhem.

Authors:  Cecilia Larocca; Thomas S Kupper; Nicole R LeBoeuf
Journal:  Clin Cancer Res       Date:  2019-10-15       Impact factor: 12.531

4.  Genetic markers associated with progression in early mycosis fungoides.

Authors:  V E Johnson; E C Vonderheid; A D Hess; C M Eischen; L Y McGirt
Journal:  J Eur Acad Dermatol Venereol       Date:  2013-10-31       Impact factor: 6.166

5.  Single-Cell Profiling of Cutaneous T-Cell Lymphoma Reveals Underlying Heterogeneity Associated with Disease Progression.

Authors:  Nicholas Borcherding; Andrew P Voigt; Vincent Liu; Brian K Link; Weizhou Zhang; Ali Jabbari
Journal:  Clin Cancer Res       Date:  2019-02-04       Impact factor: 12.531

Review 6.  Peripheral T cell lymphomas: from the bench to the clinic.

Authors:  Danilo Fiore; Luca Vincenzo Cappelli; Alessandro Broccoli; Pier Luigi Zinzani; Wing C Chan; Giorgio Inghirami
Journal:  Nat Rev Cancer       Date:  2020-04-06       Impact factor: 60.716

7.  Expression of T-plastin, FoxP3 and other tumor-associated markers by leukemic T-cells of cutaneous T-cell lymphoma.

Authors:  Elisabetta Capriotti; Eric C Vonderheid; Christopher J Thoburn; Mariusz A Wasik; David W Bahler; Allan D Hess
Journal:  Leuk Lymphoma       Date:  2008-06

8.  Regulation gone wrong: a subset of Sézary patients have malignant regulatory T cells.

Authors:  Rachael A Clark
Journal:  J Invest Dermatol       Date:  2009-12       Impact factor: 8.551

9.  STAT5-mediated expression of oncogenic miR-155 in cutaneous T-cell lymphoma.

Authors:  Katharina L Kopp; Ulrik Ralfkiaer; Lise Mette R Gjerdrum; Rikke Helvad; Ida H Pedersen; Thomas Litman; Lars Jønson; Peter H Hagedorn; Thorbjørn Krejsgaard; Robert Gniadecki; Charlotte M Bonefeld; Lone Skov; Carsten Geisler; Mariusz A Wasik; Elisabeth Ralfkiaer; Niels Ødum; Anders Woetmann
Journal:  Cell Cycle       Date:  2013-05-15       Impact factor: 4.534

10.  Different subsets of tumor infiltrating lymphocytes correlate with NPC progression in different ways.

Authors:  Yi-Lan Zhang; Jiang Li; Hao-Yuan Mo; Fang Qiu; Li-Min Zheng; Chao-Nan Qian; Yi-Xin Zeng
Journal:  Mol Cancer       Date:  2010-01-10       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.